Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia

Summary

This randomized phase III trial studies clofarabine to see how well it works compared with daunorubicin hydrochloride and cytarabine when followed by decitabine or observation in treating older patients with newly diagnosed acute myeloid leukemia. Drugs used in chemotherapy, such as clofarabine, daunorubicin hydrochloride, cytarabine, and decitabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more cancer cells. It is not yet known which chemotherapy regimen is more effective in treating acute myeloid leukemia.

Timeline

Start

2011-02-04

Primary completion

2021-02-22

Completion

2022-12-21

Publications

• Foran JM, Sun Z, Luger SM, Claxton DF, Lazarus HM, Arber DA, Rowe JM, Paietta E, Racevskis J, Garrett-Bakelman F, Zhang Y, Altman JK, Al-Kali A, Zheng H, Pratz KW, Broun ER, Powell BL, O'Dwyer KM, Godwin JE, Ofran Y, Litzow MR, Tallman MS. Survival after intensive therapy or clofarabine in fit older adults with acute myeloid leukemia: E2906 phase 3 trial. Blood Neoplasia. 2026 Jan 14;3(2):100194. doi: 10.1016/j.bneo.2026.100194. eCollection 2026 May.

Drugs

Indications